Capricor Therapeutics (CAPR) late Wednesday reported a Q3 net loss of $0.38 per diluted share compared with a loss of $0.25 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.36.

Revenue for the quarter ended Sept. 30 was $2.3 million, compared with $6.2 million a year earlier.

Analysts expected $3.6 million.

The biotechnology company finished the quarter with around $85 million in cash and equivalents, which it said would fund its anticipated expenses into 2027.

Price: 16.05, Change: -0.86, Percent Change: -5.09